

Supplementary Table 8. Genotype frequencies of microRNA processing genes polymorphism and ischemic stroke patients' mortality according to TOAST subgroup

Genotype	Validation set		Adjusted HR (95% CI)*	P	Validation set		Adjusted HR (95% CI)*	P	Validation set		Adjusted HR (95% CI)*	P
	Stroke LAD (n=200)	Death (n=32)			Stroke SVD (n=149)	Death (n=14)			Stroke CE (n=54)	Death (n=15)		
<i>DICER1</i> rs13078 A>T												
AA	186 (93.0)	29 (90.6)	1.000 (reference)		130 (87.2)	12 (85.7)	1.000 (reference)		49 (90.7)	15 (100.0)	1.000 (reference)	
AT	14 (7.0)	3 (9.4)	1.337 (0.399-4.477)	0.638	19 (12.8)	2 (14.3)	1.466 (0.310-6.923)	0.629	4 (7.4)	0	NA	0.978
TT	0	0			0	0			1 (1.9)	0		
Dominant (AA vs. AT+TT)			1.337 (0.399-4.477)	0.638			1.466 (0.310-6.923)	0.629			NA	0.978
Recessive (AA+AT vs. TT)			NA				NA				NA	
<i>DICER1</i> rs3742330 A>G												
AA	62 (31.0)	9 (28.1)	1.000 (reference)		40 (26.8)	3 (21.4)	1.000 (reference)		18 (33.3)	5 (33.3)	1.000 (reference)	
AG	89 (44.5)	18 (56.3)	1.612 (0.706-3.678)	0.257	78 (52.3)	8 (57.1)	1.527 (0.382-6.103)	0.549	20 (37.0)	3 (20.0)	0.687 (0.112-4.236)	0.686
GG	49 (24.5)	5 (15.6)	0.496 (0.149-1.645)	0.252	31 (20.8)	3 (21.4)	1.078 (0.201-5.775)	0.930	16 (29.6)	7 (46.7)	2.050 (0.583-7.214)	0.263
Dominant (AA vs. AG+GG)			1.217 (0.552-2.681)	0.627			1.414 (0.387-5.161)	0.600			1.649 (0.511-5.322)	0.403
Recessive (AA+AG vs. GG)			0.508 (0.193-1.334)	0.169			1.017 (0.275-3.764)	0.980			2.346 (0.760-7.246)	0.138
<i>DROSHA</i> rs6877842 C>G												
CC	188 (94.0)	32 (100.0)	1.000 (reference)		143 (96.0)	14 (100.0)	1.000 (reference)		48 (88.9)	13 (86.7)	1.000 (reference)	
CG	12 (6.0)	0	NA	0.954	5 (3.4)	0	NA	0.954	6 (11.1)	2 (13.3)	1.046 (0.232-4.723)	0.953
GG	0	0			1 (0.7)	0	NA	0.985	0	0		
Dominant (CC vs. CG+GG)			NA	0.954			NA	0.987			1.046 (0.232-4.723)	0.953
Recessive (CC+CG vs. GG)			NA				NA	0.987				
<i>DROSHA</i> rs10719 T>C												
TT	106 (53.0)	17 (53.1)	1.000 (reference)		78 (52.3)	8 (57.1)	1.000 (reference)		29 (53.7)	7 (46.7)	1.000 (reference)	
TC	82 (41.0)	12 (37.5)	0.867 (0.412-1.826)	0.708	60 (40.3)	5 (35.7)	0.868 (0.266-2.835)	0.815	18 (33.3)	4 (26.7)	2.351 (0.529-10.439)	0.261
CC	12 (6.0)	3 (9.4)	1.407 (0.393-5.034)	0.600	11 (7.4)	1 (7.1)	1.432 (0.160-12.800)	0.748	7 (13.0)	4 (26.7)	3.557 (0.859-14.735)	0.080
Dominant (TT vs. TC+CC)			0.916 (0.455-1.845)	0.806			0.906 (0.290-2.831)	0.866			2.165 (0.719-6.514)	0.170
Recessive (TT+TC vs. CC)			1.297 (0.387-4.349)	0.674			1.161 (0.144-9.367)	0.888			2.501 (0.718-8.714)	0.150
<i>RAN</i> rs14035 C>T												
CC	119 (59.5)	16 (50.0)	1.000 (reference)		89 (59.7)	7 (50.0)	1.000 (reference)		39 (72.2)	13 (86.7)	1.000 (reference)	
CT	74 (37.0)	13 (40.6)	1.182 (0.558-2.504)	0.663	54 (36.2)	5 (35.7)	1.233 (0.370-4.107)	0.733	13 (24.1)	2 (13.3)	1.027 (0.174-6.057)	0.977
TT	7 (3.5)	3 (9.4)	5.978 (1.422-25.139)	0.015	6 (4.0)	2 (14.3)	9.403 (1.542-57.337)	0.015	2 (3.7)	0	NA	0.985
Dominant (CC vs. CT+TT)			1.389 (0.684-2.820)	0.363			1.712 (0.571-5.134)	0.337			0.891 (0.159-4.981)	0.895
Recessive (CC+CT vs. TT)			3.976 (1.111-14.235)	0.034			5.223 (1.090-25.038)	0.039			NA	0.987

Supplementary Table 8. Continued

Genotype	Validation set		Adjusted HR (95% CI)*	P	Validation set		Adjusted HR (95% CI)*	P	Validation set		Adjusted HR (95% CI)*	P
	Stroke LAD (n=200)	Death (n=32)			Stroke SVD (n=149)	Death (n=14)			Stroke CE (n=54)	Death (n=15)		
XPO5 rs11077 A>C												
AA	171 (85.5)	28 (87.5)	1.000 (reference)		125 (83.9)	11 (78.6)	1.000 (reference)		48 (88.9)	13 (86.7)	1.000 (reference)	
AC	29 (14.5)	4 (12.5)	0.961 (0.324–2.848)	0.943	24 (16.1)	3 (21.4)	0.878 (0.224–3.438)	0.852	6 (11.1)	2 (13.3)	2.162 (0.357–13.092)	0.402
CC	0	0			0	0			0	0		
Dominant (AA vs. AC+CC)			0.961 (0.324–2.848)	0.943			0.878 (0.224–3.438)	0.852			2.162 (0.357–13.092)	0.402
Recessive (AA+AC vs. CC)			NA				NA				NA	

Values are presented as number (%).

TOAST, Trial of Org 10172 in Acute Stroke Treatment; LAD, large artery disease; HR, hazard ratio; CI, confidence interval; SVD, small vessel disease; CE, cardioembolism; NA, not available; RAIN, Ran GTPase; XPO5, ex-
 portin 5.

*Adjusted for age, sex, hypertension, diabetes mellitus, hyperlipidemia, and smoking status based on cox-regression analysis.